drugMR: A multi-omics pipeline for genetically anchored drug-target discovery
Listed in
This article is not in any list yet, why not save it to one of your lists.Abstract
Motivation
Genetically supported drug targets are an estimated 2.6 times more likely to succeed clinically, yet a disease association alone does not show which protein to target, in which direction, or what other effects may follow. This currently requires chaining separate tools.
Results
drugMR is a Nextflow pipeline that, from GWAS and pQTL summary statistics, runs cis -Mendelian randomisation, colocalisation, SMR-HEIDI with bulk and/or single-cell QTLs, three-trait colocalisation and a phenome-wide screen for adverse effects and repurposing. Datasets are added through a manifest, every step runs in containers on a laptop, cluster or cloud, and results are explored in a dashboard. Applied to schizophrenia with brain pQTLs, drugMR tested 2,019 proteins in 4 h 19 min and prioritised 58 proteogenomic targets, 22 with multi-omic support; 4 had potential adverse effects.
Availability and implementation
drugMR: https://github.com/guillermocomesa_nacimadevila/drugMR ; documentation: https://guillermocomesanacimadevila.github.io/drugMR/ . Demo data: https://doi.org/10.5281/zenodo.22917384 .
Article activity feed
-
drugMR: A multi-omics pipeline for genetically anchored drug-target discovery #SingleCell 🧪🧬🖥️ https://www.biorxiv.org/content/10.64898/2026.10.01.756031v1
-
drugMR: A multi-omics pipeline for genetically anchored drug-target discovery https://www.biorxiv.org/content/10.64898/2026.10.01.756031v1
-
drugMR: A multi-omics pipeline for genetically anchored drug-target discovery https://www.biorxiv.org/content/10.64898/2026.10.01.756031v1
-
